KAZIA THERAPEUTICS LTD — Form D
KAZIA THERAPEUTICS LTD of SYDNEY NSW, C3, a company, filed a Form D exempt-offering notice with the SEC on 2025-08-14. The offering totals $2.1M, of which $2.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-08-14
- Form: D
- Accession: 0001470831-25-000129
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.1M
- Amount sold: $2.1M
- Investors: 4
- Date of first sale: 2025-08-04
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-554781
Issuer
- Name: KAZIA THERAPEUTICS LTD
- CIK: 0001075880
- Entity type: Corporation
- Jurisdiction: AUSTRALIA
- Address: THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, C3, 2000
- Phone: 01161298780088
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Elissa Hansen | Executive Officer | Sydney, C3 |
| Ebru Davidson | Director | Sydney, C3 |
| Steven Coffey | Director | Sydney, C3 |
| Bryce Carmine | Director | Sydney, C3 |
| Jeffrey Bonacorda | Executive Officer | Sydney, C3 |
| John Friend | Director | Sydney, C3 |
| John Friend | Executive Officer | Sydney, C3 |
| Robert Apple | Director | Coral Gables, FL |
| Karen Krumeich | Executive Officer | SYNDEY NSW, C3 |
Other filings by this issuer (3)
More